Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma

Soochow University

Status and phase: Active, not recruiting; Phase 2

Conditions: Ovarian Carcinoma

Treatments: Biological: Cytokine-induced killer cells; Procedure: Radiofrequency ablation

Study type: Interventional

Funder types: Other

Identifiers

NCT02487693

ovarian001

Details and patient eligibility

About

The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with ovarian carcinoma.

Full description

The primary objective is to evaluate whether RFA followed by CIK transfusion can prolong survival of patients with ovarian carcinoma.

Enrollment: 50 estimated patients

Sex: Female

Ages: 30 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. patients diagnosed with FIGO stage II ovarian carcinoma;
2. cytoreductive surgery performed and 6 courses of platinum-based chemotherapy completed;
3. medical records maintain comprehensive data on treatment and follow-up;
4. no history of previous malignancies.

Exclusion criteria

1. neoadjuvant chemotherapy applied;
2. less than 6 courses of chemotherapy or more than 6 courses of chemotherapy completed;
3. medical records maintain incomplete data on treatment or follow-up;
4. history of previous malignancy.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

50 participants in 2 patient groups

RFA alone

No Intervention group

Description:

Patients undergo radiofrequency ablation alone.

RFA+CIK

Experimental group

Description:

Autologous cytokine-induced killer cells were transfer via venous one week after RFA Interventions

Treatment:

Procedure: Radiofrequency ablation

Biological: Cytokine-induced killer cells